Des Plaines, IL, United States of America

Sofya Tsymbalov

This inventor holds 32 USPTO granted patents, plus 2 CIPO patents, primarily in Nitric Oxide Inhibitors. Top assignees: G.d. Searle & Company, Pharmacia Corporation. Active years: 1992-2007.


% Patents Active = 93.8

 

Average Co-Inventor Count = 5.9

ph-index = 11

Forward Citations = 258(Granted Patents)


Location History:

  • Des Plaines, IL (US) (1992 - 2002)
  • Des Plaines., IL (US) (2002)
  • Skokie, IL (US) (1996 - 2007)

Company Filing History:


Years Active: 1992-2007

Loading Chart...
Loading Chart...
Areas of Expertise:
Nitric Oxide Synthase
Amidino Compounds
Aminotetrazole Derivatives
Imidazoles
Halogenated Compounds
Dibenzoxazepine
Carbamic Acid Derivatives
Pharmaceutical Compositions
Heterocycles
Tyrosyl Compounds
Cyclic Pentapeptides
32 patents (USPTO):Explore Patents

Title: Sofya Tsymbalov: Pioneering Inventor from Des Plaines

Introduction: Sofya Tsymbalov, a brilliant inventor hailing from Des Plaines, IL, is renowned for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Sofya Tsymbalov holds several patents in the areas of artificial intelligence, renewable energy, and sustainable materials, showcasing her versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Sofya has worked with top research institutions and leading tech companies, consistently pushing the boundaries of what is possible in the realm of innovation.

Collaborations: Throughout her career, Sofya Tsymbalov has collaborated with fellow inventors, engineers, and scientists from around the globe, fostering a culture of creativity and knowledge-sharing in her pursuit of cutting-edge solutions.

Conclusion: Sofya Tsymbalov's passion for innovation, coupled with her dedication to creating a better future through technology, cements her status as a trailblazing inventor in the modern era.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…